Amgen Oncology is leading the development of novel therapies that specifically harness the body’s T cells, pioneering the first immunooncology program using a BiTE®, or bispecific T cell engager.

Amgen Oncology:
https://www.amgenoncology.com/

Explore the world of BiTE® immunotherapy as Amgen scientists Dr. Dirk Nagorsen and Dr. Peter Kufer discuss the current cancer treatment landscape, explain how BiTE® works and offer a preview of how Amgen is bringing this technology into the future of cancer treatment.

In the last few years, cancer treatments have taken a huge step forward, with numerous drugs being approved by various regulatory agencies. These treatments are fueled by progress in immunooncology, using the body's own defenses to fight cancer.

Find Amgen on the Web:
Facebook: https://bit.ly/35Xf09E
Instagram: https://bit.ly/2SYnTKJ
Twitter: https://bit.ly/2SW2cLq
LinkedIn: https://bit.ly/2xWbS17